Long-term follow-up of the STARFlex device for closure of secundum atrial septal defect
- PMID: 19156887
- DOI: 10.1002/ccd.21710
Long-term follow-up of the STARFlex device for closure of secundum atrial septal defect
Abstract
Background: There is limited published outcome data on the STARFlex device for transcatheter closure of atrial septal defects (ASD).
Aim: To contribute to the long term outcomes of ASD device closure with the STARFlex device.
Methods: Results of a prospective FDA approved clinical trial (1999-2001) from a single institution of the STARFlex device for simple ASD was reviewed. The inclusion criteria included age >or=2 years, isolated secundum ASD, evidence of right ventricular volume overload, and maximum stretched diameter <22 mm. A retrospective review of the original study data with most recent follow-up was performed. Clinical success in the trial was defined as complete closure or residual leak <or=2 mm, absence of a severe complication and no need for an additional device or surgery to treat the ASD.
Results: Twenty seven (27) patients were prospectively enrolled in the study period with a procedural success in 23 (85%). There were two severe complications, both 40 mm device embolizations that underwent semiurgent surgical intervention for device removal and ASD closure (40 mm device subsequently withdrawn from trial). Device placement was unsuccessful in two patients due to malposition related to an insufficient retro-aortic rim, with elective surgical closure. Unsuccessful procedural outcomes were statistically associated with deficient rims (P < 0.01). Of the 23 long term follow-up device patients, 23 (100%) achieved clinical success: 22 (96%) had complete closure at 1 year and latest echocardiographic follow-up and one case had a small <2 mm residual defect that has persisted. There have been no late complications with normalization of RV volumes in 92% and no deleterious ECG changes. Device fractures occurred in 8/23 (35%) devices and were more common in the larger devices (P < 0.05) but had no sequelae. None required any further intervention to treat the ASD and there were no infectious or thrombotic issues.
Conclusions: In this cohort the STARFlex device for secundum ASD closure provided procedural success in 85% with failures due to surgical referral. All 23 patients with a STARFlex device with available long term follow-up had clinical success. Further long term data is required.
(c) 2009 Wiley-Liss, Inc.
Comment in
-
Long-term follow-up of the Starflex device for closure of secundum atrial septal defect.Catheter Cardiovasc Interv. 2009 Feb 1;73(2):196. doi: 10.1002/ccd.21956. Catheter Cardiovasc Interv. 2009. PMID: 19156889 No abstract available.
Similar articles
-
Device closure rates of simple atrial septal defects optimized by the STARFlex device.J Am Coll Cardiol. 2006 Aug 1;48(3):538-44. doi: 10.1016/j.jacc.2006.03.049. Epub 2006 Jul 12. J Am Coll Cardiol. 2006. PMID: 16875981
-
Initial clinical experience with the GORE® CARDIOFORM ASD occluder for transcatheter atrial septal defect closure.Catheter Cardiovasc Interv. 2017 Sep 1;90(3):495-503. doi: 10.1002/ccd.26907. Epub 2017 Jan 27. Catheter Cardiovasc Interv. 2017. PMID: 28128523
-
[Transcatheter closure of secundum atrial septal defect in children].Zhonghua Er Ke Za Zhi. 2004 Apr;42(4):287-90. Zhonghua Er Ke Za Zhi. 2004. PMID: 15157392 Clinical Trial. Chinese.
-
Fenestrated Transcatheter ASD Closure in Adults with Diastolic Dysfunction and/or Pulmonary Hypertension: Case Series and Review of the Literature.Congenit Heart Dis. 2016 Dec;11(6):663-671. doi: 10.1111/chd.12367. Epub 2016 Apr 29. Congenit Heart Dis. 2016. PMID: 27125263 Review.
-
Interventional Therapy Versus Medical Therapy for Secundum Atrial Septal Defect: A Systematic Review (Part 2) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019 Apr 2;139(14):e814-e830. doi: 10.1161/CIR.0000000000000605. Circulation. 2019. PMID: 30586769
Cited by
-
Long-Term Results after Percutaneous Closure of Atrial Septal Defect: Cardiac Remodeling and Quality of Life.J Cardiovasc Echogr. 2013 Apr-Jun;23(2):53-59. doi: 10.4103/2211-4122.123028. J Cardiovasc Echogr. 2013. PMID: 28465884 Free PMC article.
-
Comparative Study between Surgical Repair of Atrial Septal Defect via Median Sternotomy, Right Submammary Thoracotomy, and Right Vertical Infra-Axillary Thoracotomy.Braz J Cardiovasc Surg. 2020 Jun 1;35(3):285-290. doi: 10.21470/1678-9741-2019-0096. Braz J Cardiovasc Surg. 2020. PMID: 32549099 Free PMC article.
-
Midterm follow-up of transthoracic device closure of an atrial septal defect using the very large domestic occluder (44-48 mm), a single Chinese cardiac center experience.J Cardiothorac Surg. 2017 Sep 2;12(1):74. doi: 10.1186/s13019-017-0639-8. J Cardiothorac Surg. 2017. PMID: 28865489 Free PMC article.
-
Impact of the Amplatzer atrial septal occluder device on left ventricular function in pediatric patients.Pediatr Cardiol. 2013 Oct;34(7):1645-51. doi: 10.1007/s00246-013-0695-3. Epub 2013 Apr 17. Pediatr Cardiol. 2013. PMID: 23591799
-
Multiple transcatheter interventions in the same session in congenital cardiopathies.J Cardiovasc Dis Res. 2010 Oct;1(4):181-90. doi: 10.4103/0975-3583.74261. J Cardiovasc Dis Res. 2010. PMID: 21264182 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources